Inside the research

Cencora, Inc.

COR Research profile · latest available data

Price overview

$306.92

▼ -2.95 (-1.0%)

52w hi$372.53
52w lo$251.67
Vol1.04M
As of25 Sep 2026

The Verdict

Hold

Our score +0.18

Short+0.10
Medium+0.28
Long+0.15

computed 2026-09-27

Key fundamentals

Cencora, Inc.

Healthcare · Medical Distribution

Market cap$58.57B
Enterprise value$70.40B
Trailing P/E22.79x
Forward P/E15.48x
EV / EBITDA12.69x
P / S (ttm)0.18x
Profit margin0.8%
Return on equity96.9%
Revenue growth+5.1%
Earnings growth+11.9%
Debt / equity446.52

Layer Breakdown

LayerRawContribution
Fundamental+0.18
Sector+0.08
Technical+0.09
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

United States · www.cencora.com

Risk Metrics

Beta vs SPX-0.03
Corr SPX-0.02
Annual vol26.7%
Annual ret+18.5%
Sharpe0.69
Max DD-32.6%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$365.17
High / Low$429.00 / $280.00
Median$361.50
Analysts12
Strong Buy4
Buy8
Hold2
Sell0
Strong Sell0

Recent rating actions

2026-05-07UBS→ Buy
2026-05-07Evercore ISI Group→ Outperform
2026-05-07Citigroup→ Buy
2026-05-07Baird→ Outperform
2026-04-28William Blair→ Market Perform
2026-04-08Evercore ISI Group→ Outperform

Officers & Board

DirectorLorence Kim since 2022
DirectorDennis M. Nally since 2020
DirectorMark Durcan since 2015
DirectorOrnella Barra since 2015
DirectorLon R. Greenberg since 2013
CEOSteven H. Collis since 2011
DirectorSteven H. Collis since 2011
DirectorKathleen W. Hyle since 2010
DirectorRichard W. Gochnauer since 2008
DirectorMichael J. Long since 2006
DirectorHenry W. McGee since 2004
DirectorJane E. Henney since 2002

Material Events

DateEvent8-K
2026-08-14Officer / Director Changeread
2026-08-12Reg FD Disclosureread
2026-08-05Earnings Release, Reg FD Disclosure…read
2026-08-05Material Agreement, Material Obligation…read
2026-06-15Officer / Director Change, Reg FD Disclosure…read
2026-05-29Officer / Director Change, Reg FD Disclosure…read
2026-05-06Earnings Release, Reg FD Disclosure…read
2026-03-23Reg FD Disclosure, Exhibitsread
2026-03-17Officer / Director Change, Reg FD Disclosure…read
2026-03-06Shareholder Voteread
2026-02-18Reg FD Disclosure, Other Material Event…read
2026-02-13Material Agreement, Material Obligation…read

Insider Trades

DateInsiderRoleActionSharesValue
2026-07-31NALLY DENNIS MGrant113$35.18K
2026-07-31Cooper EllenGrant97$30.20K
2026-07-31Tyler Lauren MGrant97$30.20K
2026-06-30Battaglia SilvanaExecutive Vice PresidentGrant58$14.00K
2026-06-30Campbell Elizabeth SExecutive Vice PresidentGrant50$12.00K
2026-06-22Tyler Lauren MBuy550$148.63K
2026-06-18DURCAN DERMOT MARKBuy4.00K$1.10M
2026-05-28DURCAN DERMOT MARKBuy4.00K$1.07M
2026-05-01Tyler Lauren MGrant99$30.10K

Flow & Concentration

Insider 180d net$2.31M
Insider buys / sells3 / 0
Insider biasBuyers
13F holders9
Top-5 share98.0%
HHI3,694 (concentrated)

Top Holders

HolderValueShares
State Street Corp$2.62B9.27M
Fidelity / FMR LLC$1.17B4.12M
Citadel Advisors$467.72M1.65M
Millennium Management$278.02M982.48K
Capital Research / Capital World$189.53M669.75K
AQR Capital Management$76.38M272.73K
Bridgewater Associates$9.63M34.05K
Renaissance Technologies$6.68M23.62K
T. Rowe Price Group$2.02M7.13M

As of 2026-06-30

Dividends

Yield (TTM)0.39%
$ / share (TTM)$1.20
5y CAGR-19.3%

Annual dividend per share

2021$6.82
2022$1.87
2023$1.97
2024$2.08
2025$2.25
2026$0.60

Federal Contracts

AmountAgencyDescription
$22.05KDepartment of Veterans AffairsPHARMACY ORDER WELIREG 40MG
$18.13KDepartment of Veterans AffairsPHARMACY ORDER BALVERSA 4MG TABS
$18.13KDepartment of Veterans AffairsPHARMACY ORDER BALVERSA 4MG TABLETS
$17.64KDepartment of Veterans AffairsPHARMACY ORDER BALVERSA 4MG TABS
$17.64KDepartment of Veterans AffairsPHARMACY ORDER BALVERSA 4MG TABS
$11.81KDepartment of Veterans AffairsPHARMACY ORDER BALVERSA 5MG TABLETS
$11.81KDepartment of Veterans AffairsPHARMACY ORDER BALVERSA 5MG TABLETS
$11.25KDepartment of Veterans AffairsPHARMACY ORDER BALVERSA 5MG TABLETS

SEC Filings

DateFormDoc
2026-08-148-Kview
2026-08-128-Kview
2026-08-058-Kview
2026-08-0510-Qview
2026-08-058-Kview
2026-08-044view
2026-08-044view
2026-08-044view
2026-07-074view
2026-07-074view
2026-06-303view
2026-06-304view
2026-06-244view
2026-06-224view
2026-06-1811-Kview

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$321.33B+10.0%
Gross profit$8.96B+9.1%
Operating income$2.63B+7.1%
Net income$1.55B+8.9%
Cash from ops$3.88B+10.5%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$308.95$310.89$304.31$306.921.04M
Sep 24$313.32$316.61$309.18$309.871.08M
Sep 23$315.51$320.24$310.71$312.281.10M
Sep 22$317.62$320.00$313.89$314.43775.70K
Sep 21$309.74$316.98$308.51$316.491.05M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →